Trial
NCT05034874
Multiple-Dose Study to Evaluate the Safety and Efficacy of IXT-m200
Phase IITERMINATEDEFFICACY/FUTILITYConfidence: MEDIUM
Sponsor
InterveXion Therapeutics, LLC
Collaborators
National Institute on Drug Abuse (NIDA)
Condition
Methamphetamine-dependence
Intervention
IXT-m200
Why stopped
Interim analysis concluded planned study numbers combined with participant dropout rates were insufficient to meet primary endpoint.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2024-10-04